Gallen International Expert Consensus recommendations were further subclassified into three subtypes (traditionally considered “favorable” subtype-ER+/PR+/HER2−, and traditionally considered “unfavorable” BC subtypes: HER2+ and triple negative). Here, ERBB2 is linked to breast cancer.